Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies

Dana Faratian; Annelien J M Zweemer; Yoko Nagumo; Andrew Sims; Morwenna Muir; Michael Dodds; Peter Mullen; Inhwa Um; Charlene Kay; Max Hasmann; David J Harrison; Simon P Langdon

doi:10.1158/1078-0432.CCR-10-2461

Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies

Dana Faratian, Annelien J M Zweemer, Yoko Nagumo, Andrew Sims, Morwenna Muir, Michael Dodds, Peter Mullen, Inhwa Um, Charlene Kay, Max Hasmann, David J Harrison, Simon P Langdon

Research output: Contribution to journal › Article › peer-review

Abstract

The aim of this study was to investigate the antitumor effects of HER2-directed combination therapy in ovarian cancer xenograft models to evaluate their potential. The combinations of trastuzumab and pertuzumab, and trastuzumab and aromatase inhibitor therapy were investigated.

Original language	English
Pages (from-to)	4451-61
Number of pages	11
Journal	Clinical Cancer Research
Volume	17
Issue number	13
DOIs	https://doi.org/10.1158/1078-0432.CCR-10-2461
Publication status	Published - 2011

Access to Document

10.1158/1078-0432.CCR-10-2461

Cite this

Faratian, D., Zweemer, A. J. M., Nagumo, Y., Sims, A., Muir, M., Dodds, M., Mullen, P., Um, I., Kay, C., Hasmann, M., Harrison, D. J., & Langdon, S. P. (2011). Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies. Clinical Cancer Research, 17(13), 4451-61. https://doi.org/10.1158/1078-0432.CCR-10-2461

@article{9ad4489bf4594b068bf55eb2ec189de0,

title = "Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies",

abstract = "The aim of this study was to investigate the antitumor effects of HER2-directed combination therapy in ovarian cancer xenograft models to evaluate their potential. The combinations of trastuzumab and pertuzumab, and trastuzumab and aromatase inhibitor therapy were investigated.",

author = "Dana Faratian and Zweemer, {Annelien J M} and Yoko Nagumo and Andrew Sims and Morwenna Muir and Michael Dodds and Peter Mullen and Inhwa Um and Charlene Kay and Max Hasmann and Harrison, {David J} and Langdon, {Simon P}",

year = "2011",

doi = "10.1158/1078-0432.CCR-10-2461",

language = "English",

volume = "17",

pages = "4451--61",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "13",

}

Faratian, D, Zweemer, AJM, Nagumo, Y, Sims, A, Muir, M, Dodds, M, Mullen, P, Um, I, Kay, C, Hasmann, M, Harrison, DJ & Langdon, SP 2011, 'Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies', Clinical Cancer Research, vol. 17, no. 13, pp. 4451-61. https://doi.org/10.1158/1078-0432.CCR-10-2461

TY - JOUR

T1 - Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies

AU - Faratian, Dana

AU - Zweemer, Annelien J M

AU - Nagumo, Yoko

AU - Sims, Andrew

AU - Muir, Morwenna

AU - Dodds, Michael

AU - Mullen, Peter

AU - Um, Inhwa

AU - Kay, Charlene

AU - Hasmann, Max

AU - Harrison, David J

AU - Langdon, Simon P

PY - 2011

Y1 - 2011

N2 - The aim of this study was to investigate the antitumor effects of HER2-directed combination therapy in ovarian cancer xenograft models to evaluate their potential. The combinations of trastuzumab and pertuzumab, and trastuzumab and aromatase inhibitor therapy were investigated.

AB - The aim of this study was to investigate the antitumor effects of HER2-directed combination therapy in ovarian cancer xenograft models to evaluate their potential. The combinations of trastuzumab and pertuzumab, and trastuzumab and aromatase inhibitor therapy were investigated.

UR - http://www.scopus.com/inward/record.url?scp=79960304114&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-10-2461

DO - 10.1158/1078-0432.CCR-10-2461

M3 - Article

C2 - 21571868

SN - 1078-0432

VL - 17

SP - 4451

EP - 4461

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 13

ER -

Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies

Abstract

Access to Document

Other files and links

Fingerprint

Cite this